Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul 31;14(7):2364-2368.
doi: 10.21037/tlcr-2025-466. Epub 2025 Jul 16.

Lorlatinib in ALK-positive non-small cell lung cancer: final survival data that reshape the therapeutic landscape

Yuki Katayama  1
Affiliations
Editorial

Lorlatinib in ALK-positive non-small cell lung cancer: final survival data that reshape the therapeutic landscape

Yuki Katayama. Transl Lung Cancer Res. .
No abstract available

Keywords: Anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK-positive NSCLC); central nervous system metastases (CNS metastases); long-term survival; lorlatinib; tyrosine kinase inhibitors (TKIs).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-466/coif). Y.K. has received research grant support from the Japan Lung Cancer Society, SGH Foundation, and the Japan Research Foundation for Clinical Pharmacology. These grants were administered through the author’s affiliated institution and are unrelated to the submitted work. The author has no other conflicts of interest to declare.

Comment on

References

    1. Ou SI, Solomon BJ, Besse B, et al. Final overall survival and long-term safety of lorlatinib in patients with ALK-positive NSCLC from the pivotal phase 2 study: a brief report. J Thorac Oncol 2025;20:513-20. 10.1016/j.jtho.2024.11.021 - DOI - PubMed
    1. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 2020;31:1056-64. 10.1016/j.annonc.2020.04.478 - DOI - PubMed
    1. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2018;379:2027-39. 10.1056/NEJMoa1810171 - DOI - PubMed
    1. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. J Thorac Oncol 2021;16:2091-108. 10.1016/j.jtho.2021.07.035 - DOI - PubMed
    1. Solomon BJ, Bauer TM, Mok TSK, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med 2023;11:354-66. 10.1016/S2213-2600(22)00437-4 - DOI - PubMed